



Organizing Committee

Markus Graefen & Derya Tilki

@ tilki@martini-klinik.de

Martini-Klinik, Martinistraße 52, 20246 Hamburg

Registration

Early bird until July 15, 2019

Regular fee € 290,00

Reduced fee for GeSRU member & assistant physician € 235,00

Late fee after July 15, 2019

Regular fee € 340,00

Day tickets

Thursday, August 22nd € 100,00

Friday, August 23rd € 215,00

Saturday, August 24th € 110,00

Please sign up at www.martini-klinik.de/summit

The event will be accredited with CME points.

Meeting Venue

Sofitel Hotel Hamburg Alter Wall

Alter Wall 40, 20457 Hamburg, Germany



Platinum Sponsor



Gold Sponsor



Silver Sponsor



Bronze Sponsors



Special Support



At the time of going to press. Recent sponsors and detailed information according to the FSA transparency codex can be found on the Summit's website.

The

Hamburg Prostate Cancer Summit

August 22 - 24, 2019



International Expertise meets in Hamburg!

Internationally renowned prostate cancer specialists will share their expertise and knowledge.

The program of the three day summit will be filled with lively discussions on most pressing topics in the field of prostate cancer, such as focal therapy, mpMRI, germline testing, PSMA theranostics, optimal management of newly diagnosed metastatic prostate cancer and metastasis-directed therapy.

We are looking forward to welcoming you in Hamburg!

On behalf of the Martini-Klinik

M. Graefen & D. Tilki

Program

Faculty at a Glance

Peter Albertsen
Farmington, USA

Himisha Beltran
Boston, USA

Alberto Bossi
Villejuif, France

Robert Bristow
Manchester, UK

Noel Clarke
Manchester, UK

Matthew Cooperberg
San Francisco, USA

Anthony D'Amico
Boston, USA

Mark Emberton
London, UK

Christopher Evans
Sacramento, USA

Silke Gillessen
Manchester, UK

Martin Gleave
Vancouver, Canada


Michael Hofman
Melbourne, Australia




Maha Hussain
Chicago, USA



Laurence Klotz
Toronto, Canada


Declan Murphy
Melbourne, Australia



Christian Stief
Munich, Germany

Day 1	Thursday, August 22nd
5:00 pm	Welcome Drink & Registration
5:50 pm	Opening Remarks D. Tilki & M. Graefen
Session 1:	Inspirational Talks
Moderators:	M. Graefen & H. Huland
6:00 pm	Advanced Prostate Cancer: Standards of Care, Challenges, Progress & Personalized Therapy M. Hussain
6:30 pm	A glimpse of the future M. Emberton
7:00 pm	 Welcome Reception
Day 2	Friday, August 23rd
Session 2:	Screening / Genomics / Imaging
Moderators:	R. Bristow & D. Murphy
8:00 am	Screening for Prostate Cancer: What have we learned in the last three decades? P. Albertsen
8:20 am	Genomics in Prostate Cancer C. Evans
Panel:	Germline Testing Chair: D. Murphy; Panelists: H. Beltran, R. Bristow, N. Clarke
8:40 am	Who should have Germline Testing? H. Beltran
9:00 am	Case Presentations and Panel Discussion
9:30 am	High resolution ultrasound - a new paradigm for diagnosis of Prostate Cancer L. Klotz
Debate:	Bi-parametric MRI i s sufficient for early detection of Prostate Cancer
9:50 am	Dynamic contrast-enhanced imaging (DCE) can be omitted M. Emberton

10:05 am	CON: DCE provides critical information P. Albertsen
10:20 am	Rebuttal & Open Discussion
10:30 am	
 Heinrich Warner Stiftung	Symposium 11:00 pm - 1:00 pm
Treatment of Localized Prostate Cancer	
Moderators:	C. Evans & M. Gleave
11:00 am	Active Surveillance 2019: how to do it safely and what’s on the horizon M. Cooperberg
11:20 am	Focal therapy - concept and application L. Klotz
11:40 am	Robotic versus open prostatectomy: an update to the never-ending debate C. Stief
12:00 pm	Hypofractionated Radiotherapy for Prostate Cancer: a new standard? A. Bossi
12:20 pm	Is there a best way to treat localized Prostate Cancer? M. Cooperberg
12:40 pm	Adjuvant versus Salvage post prostatectomy treatment A. D’Amico
1:00 pm	 Lunch
Fireside chat:	2:00 pm - 2:30 pm
2:00 pm	Exploring the way Active Surveillance is set to change M. Emberton & L. Klotz
2:20 pm	Open Discussion
Session 3:	High risk / Metastatic Prostate Cancer
Moderators:	P. Albertsen & M. Cooperberg
2:40 pm	Treatment of Men with High Risk Prostate Cancer A. D’Amico
3:00 pm	Neoadjuvant Therapies in High Risk Localized Prostate Cancer – Past, Present and Future M. Gleave

Debate:	Metastasis-directed therapy is a useful strategy for metastatic Prostate Cancer
3:20 pm	PRO: Metastasis-directed therapy is a useful strategy A. Bossi
3:35 pm	CON: Metastasis-directed therapy is useless D. Murphy
3:50 pm	Rebuttal & Open Discussion
4:00 pm	
 astellas	Symposium 4:30 pm - 5:30 pm
Changing Environment in the Treatment of Advanced Prostate Cancer	
Moderator:	C. Evans
4:30 pm	Introduction
4:35 pm	Treatment of castration-sensitive metastatic Prostate Cancer C. Evans
4:50 pm	Changing therapeutic landscape of non-metastatic castration-resistant Prostate Cancer M. Hussain
5:05 pm	Stress adaptation, plasticity and evolution as drivers of treatment resistance in Prostate Cancer M. Gleave
5:20 pm	Discussion

Day 3	Saturday, August 24th
 Janssen Oncology	Symposium 9:00 am - 9:30 am
Advanced Prostate Cancer Management	
Moderator:	D. Murphy
9:00 am	The missing piece of the castration-sensitive metastatic Prostate Cancer puzzle D. Murphy
9:15 am	The rich future of Prostate Cancer therapy N. Clarke

Session 4:	Metastatic Prostate Cancer
Moderators:	H. Beltran & M. Hussain
9:40 am	Precision guided munitions using PSMA theranostics to target Prostate Cancer M. Hofman
10:00 am	Role of local treatment in the management of low volume castration-sensitive metastatic Prostate Cancer A. D’Amico
10:20 am	Planning and initiating trials in the „Oligometastatic“ space: STAMPEDE Arm M N. Clarke
10:40 am	Treatment sequencing in metastatic castration-resistant Prostate Cancer S. Gillesen
11:00 am	
Session 5:	Hot topics / Controversies
Moderators:	M. Graefen & D. Tilki
11:30 am	The Tumour Microenvironment and Prostate Cancer Genetics: Time for Heresy! R. Bristow
11:50 am	Brachytherapy for PCa: still a valid option? A. Bossi
12:05 pm	PSMA PET Imaging in Prostate Cancer: Should it replace conventional Imaging or be used as an additional tool M. Hofman
12:20 pm	„Volume“, „Risk“ and Outcome in the STAMPEDE trial: Opinion meets biology N. Clarke
12:35 pm	Accepting the uncertainties of prostate MRI – implications for diagnosis and focal therapy D. Murphy
12:50 pm	Closing Remarks M. Graefen & D. Tilki
1:00 pm	 Lunch